MELBOURNE – BioMarin Pharmaceutical Inc has agreed to acquire Amicus Therapeutics Inc in an all-cash deal valued at approximately $4.8 billion, the companies said on Monday. The acquisition includes Amicus’s commercial licensing contract for Dimerix Ltd’s experimental kidney disease therapy, DMX-200. Under the definitive agreement, BioMarin will assume all rights and obligations from Amicus…